Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13737)	6/1/2000 11:56:00 AM
From: ballydog1	Read Replies (1) \| Respond to of 17367

Blue, Agreed, no financial gain if data is "lousy". Conflict is only in getting a drug approved with lousy data for financial gain. Let Bax/Xoma be the one's to insist the data is good, great, fabulous! In writing, in a peer reviewed journal! Then they will get the appropriate support. Our politicians are only able to decipher what they want to when politically motivated to do so. It would be skipping a step imho to release raw, unanalyzed, un-interpreted data. Yes, give Neuprex ASAP to the afflicted kids under compassionate use if possible. Same as with Aids or Cancer. Theoretically, the FDA approves drugs that are proven safe and effective without politics (at least we have the safe part nailed). In reality, we may know differently. Of course reasonable people may differ. A lawyers phrase. No, I don't need any more Xoma. I have enough.